{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T20:42:47Z","timestamp":1790800967366,"version":"4.1.0"},"reference-count":22,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"17","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2009,11,13]]},"DOI":"10.1097\/qad.0b013e3283316a5e","type":"journal-article","created":{"date-parts":[[2009,10,28]],"date-time":"2009-10-28T03:22:47Z","timestamp":1256700167000},"page":"2289-2300","source":"Crossref","is-referenced-by-count":152,"title":["Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials"],"prefix":"10.1097","volume":"23","author":[{"given":"Christine","family":"Katlama","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard","family":"Haubrich","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jacob","family":"Lalezari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Adriano","family":"Lazzarin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jos\u00e9 V","family":"Madruga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jean-Michel","family":"Molina","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mauro","family":"Schechter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monika","family":"Peeters","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaston","family":"Picchio","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Vingerhoets","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Woodfall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Goedele","family":"De Smedt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","reference":[{"key":"R1-6-20210130","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1089\/08892220260190308","article-title":"Cross-resistance among nonnucleoside reverse transcriptase inhibitors limits recycling efavirenz after nevirapine failure","volume":"18","author":"Antinori","year":"2002","journal-title":"AIDS Res Hum Retroviruses"},{"key":"R2-6-20210130","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1002\/jmv.2055","article-title":"Resistance profile and cross-resistance of HIV-1 among patients failing a nonnucleoside reverse transcriptase inhibitor-containing regimen","volume":"65","author":"Delaugerre","year":"2001","journal-title":"J Med Virol"},{"key":"R4-6-20210130","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1310\/3Q91-YT2D-BUT4-8HN6","article-title":"Safety and tolerance of efavirenz in different antiretroviral regimens: results from a national multicenter prospective study in 1,033 HIV-infected patients","volume":"3","author":"Perez-Molina","year":"2002","journal-title":"HIV Clin Trials"},{"key":"R5-6-20210130","doi-asserted-by":"crossref","first-page":"1253","DOI":"10.1016\/S0140-6736(04)15997-7","article-title":"Comparison of first-line antiretroviral therapy with regimens including nevirapine, efavirenz, or both drugs, plus stavudine and lamivudine: a randomised open-label trial, the 2NN Study","volume":"363","author":"van Leth","year":"2004","journal-title":"Lancet"},{"key":"R6-6-20210130","doi-asserted-by":"crossref","first-page":"825","DOI":"10.1086\/428093","article-title":"Severe hepatotoxicity associated with nevirapine use in HIV-infected subjects","volume":"191","author":"Sanne","year":"2005","journal-title":"J Infect Dis"},{"key":"R9-6-20210130","doi-asserted-by":"crossref","first-page":"4680","DOI":"10.1128\/AAC.48.12.4680-4686.2004","article-title":"TMC125, a novel next-generation nonnucleoside reverse transcriptase inhibitor active against nonnucleoside reverse transcriptase inhibitor-resistant human immunodeficiency virus type 1","volume":"48","author":"Andries","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"R10-6-20210130","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S0140-6736(07)61047-2","article-title":"Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-1: 24-week results from a randomised, double-blind, placebo-controlled trial","volume":"370","author":"Madruga","year":"2007","journal-title":"Lancet"},{"key":"R11-6-20210130","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1016\/S0140-6736(07)61048-4","article-title":"Efficacy and safety of TMC125 (etravirine) in treatment-experienced HIV-1-infected patients in DUET-2: 24-week results from a randomised, double-blind, placebo-controlled trial","volume":"370","author":"Lazzarin","year":"2007","journal-title":"Lancet"},{"key":"R12-6-20210130","first-page":"125","article-title":"Update of the drug resistance mutations in HIV-1: fall 2005","volume":"13","author":"Johnson","year":"2005","journal-title":"Top HIV Med"},{"key":"R13-6-20210130","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/S0197-2456(01)00179-9","article-title":"The evaluation of subcutaneous proleukin (interleukin-2) in a randomized international trial: rationale, design, and methods of ESPRIT","volume":"23","author":"Emery","year":"2002","journal-title":"Control Clin Trials"},{"key":"R14-6-20210130","first-page":"A26","article-title":"An update of the list of NNRTI mutations associated with decreased virological response to etravirine: multivariate analyses on the pooled DUET-1 and DUET-2 clinical trial data","volume":"13","author":"Vingerhoets","year":"2008","journal-title":"Antivir Ther"},{"key":"R15-6-20210130","first-page":"A133","article-title":"Determination of phenotypic clinical cut-offs for etravirine: pooled Week 24 results of the DUET-1 and DUET-2 trials","volume":"13","author":"Peeters","year":"2008","journal-title":"Antivir Ther"},{"key":"R16-6-20210130","first-page":"119","article-title":"Update of the drug resistance mutations in HIV-1: 2007","volume":"15","author":"Johnson","year":"2007","journal-title":"Top HIV Med"},{"key":"R17-6-20210130","doi-asserted-by":"crossref","first-page":"827","DOI":"10.1001\/jama.296.7.827","article-title":"Treatment for adult HIV infection. 2006 recommendations of the International AIDS Society \u2013 USA Panel","volume":"296","author":"Hammer","year":"2006","journal-title":"JAMA"},{"key":"R18-6-20210130","doi-asserted-by":"crossref","first-page":"65","DOI":"10.1111\/j.1468-1293.2007.00533.x","article-title":"European AIDS Clinical Society (EACS) guidelines for the clinical management and treatment of HIV-infected adults","volume":"9","author":"Clumeck","year":"2008","journal-title":"HIV Med"},{"key":"R19-6-20210130","doi-asserted-by":"crossref","first-page":"487","DOI":"10.1111\/j.1468-1293.2006.00424.x","article-title":"British HIV Association (BHIVA) guidelines for the treatment of HIV-infected adults with antiretroviral therapy (2006)","volume":"7","author":"Gazzard","year":"2006","journal-title":"HIV Med"},{"key":"R20-6-20210130","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/S0140-6736(04)17055-4","article-title":"Codevelopment of new antiretrovirals in very treatment-experienced HIV-infected individuals","volume":"364","author":"Youle","year":"2004","journal-title":"Lancet"},{"key":"R21-6-20210130","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1016\/S0140-6736(07)60497-8","article-title":"Efficacy and safety of darunavir-ritonavir at week 48 in treatment-experienced patients with HIV-1 infection in POWER 1 and 2: a pooled subgroup analysis of data from two randomised trials","volume":"369","author":"Clotet","year":"2007","journal-title":"Lancet"},{"key":"R22-6-20210130","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0140-6736(07)61022-8","article-title":"No patient left behind: better treatments for resistant HIV infection","volume":"370","author":"Hirschel","year":"2007","journal-title":"Lancet"},{"key":"R23-6-20210130","doi-asserted-by":"crossref","first-page":"12773","DOI":"10.1128\/JVI.79.20.12773-12782.2005","article-title":"TMC125 displays a high genetic barrier to the development of resistance: evidence from in vitro selection experiments","volume":"79","author":"Vingerhoets","year":"2005","journal-title":"J Virol"},{"key":"R30-6-20210130","doi-asserted-by":"crossref","first-page":"711","DOI":"10.1086\/511433","article-title":"Persistence of K103N-containing HIV-1 variants after single-dose nevirapine for prevention of HIV-1 mother-to-child transmission","volume":"195","author":"Flys","year":"2007","journal-title":"J Infect Dis"},{"key":"R31-6-20210130","doi-asserted-by":"crossref","first-page":"550","DOI":"10.1128\/CMR.00017-07","article-title":"Clinical significance of human immunodeficiency virus type 1 replication fitness","volume":"20","author":"Dykes","year":"2007","journal-title":"Clin Microbiol Rev"}],"container-title":["AIDS"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.ovid.com\/00002030-200911130-00006","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,6]],"date-time":"2026-08-06T18:05:14Z","timestamp":1786039514000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.ovid.com\/00002030-200911130-00006"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2009,11,13]]},"references-count":22,"journal-issue":{"issue":"17","published-print":{"date-parts":[[2009]]}},"URL":"https:\/\/doi.org\/10.1097\/qad.0b013e3283316a5e","relation":{},"ISSN":["0269-9370"],"issn-type":[{"value":"0269-9370","type":"print"}],"subject":[],"published":{"date-parts":[[2009,11,13]]}}}